Methylprednisolone improves survival in liver failure due to hepatitis B: Study
China: The use of methylprednisolone (MP) is a safe and effective treatment for hepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) increasing the survival rate of 6 months, reveals a recent study in the journal BMC Medicine.
In Asia, HBV-ACLF accounts for about 70% of all ACLF cases, which is identified with severe acute exacerbation (AE) of liver function to liver failure in chronic hepatitis B (CHB) patients with high mortality. Only curative treatment for ACLF is liver transplantation with limited application. Up til now no effective treatment has been developed for HBV-ACLF patients. The use of MP in HBV-ACLF is still controversial.
Qing-Hua Meng, Capital Medical University, Beijing, China, and colleagues aimed to evaluate the efficacy and safety of MP in HBV-ACLF.
It included a total of 171 HBV-ACLF patients from three medical centers. They were randomly allocated into two groups. MP group consisted of 2 patients treated with intravenously guttae for 7 days plus standard treatment: 1.5 mg/kg/day [day 1–3], 1 mg/kg/day [day 4–5], and 0.5 mg/kg/day [day 6–7]. Control group consisted of 88 patients treated with standard treatment.
The primary endpoints were 6-month mortality and prognostic factors for 6-month survival. The survival time, cause of death, adverse events, liver function, and HBV DNA replication were analyzed.
Key findings of the study include:
- The 6-month mortality was significantly lower in MP group than control group [32.4% vs. 42.5%].
- MP treatment was an independent prognostic factor for 6-month survival [HR 0.547].
- Factors associated with reduced 6-month mortality in MP group included HBV DNA and lymphocyte/monocyte ratio (LMR).
- Based on ROC curve, LMR+MELD had a better predictive value for prognosis of HBV-ACLF under MP treatment.
- No significant difference in HBV DNA replication was observed between groups.
"Our findings demonstrate that MP therapy is an effective and safe clinical strategy in HBV-ACLF, increasing the 6-month survival rate," concluded the authors.
"The efficacy and safety of methylprednisolone in hepatitis B virus-related acute-on-chronic liver failure: a prospective multi-center clinical trial," is published in the journal BMC Medicine.
DOI: https://bmcmedicine.biomedcentral.com/articles/10.1186/s12916-020-01814-4
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.